A Phase 3 interventional study of CD07805/47 gel 0.5% in Rosacea, sponsored by Galderma R&D. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.
Among the 11 studies testing brimonidine in Rosacea, this one is the 2nd largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 3, and was the 4th registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →
brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2011.
This study's enrollment of 449 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 205 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 4 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
28 studies in Rosacea by Galderma Group AG: none open now, none under way, none of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 28 studies in Rosacea by Galderma Group AG, this one is the 6th largest by enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2011, is one of 11 in phase 3, and was the 11th registered.
Galderma Group AG’s Rosacea studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing brimonidine in Rosacea, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 28 in Rosacea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: CD07805/47 gel 0.5%
Drug page: Brimonidine
In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea.
Static evaluation of erythema severity using the Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema 1. / Almost clear; slight redness 2. / Mild erythema; definite redness 3. / Moderate erythema; marked redness 4. / Severe erythema; fiery redness Change in CEA from Baseline CEA (T0 at Baseline visit Day 1) at T3 of each post-baseline visit, including Day 1.
Time frame: Over 1 year
| Milestone | CD07805/47 Gel 0.5% |
|---|---|
| Started | 449 |
| Completed | 279 |
| Not completed | 170 |
Static evaluation of erythema severity using the Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema 1. / Almost clear; slight redness 2. / Mild erythema; definite redness 3. / Moderate erythema; marked redness 4. / Severe erythema; fiery redness Change in CEA from Baseline CEA (T0 at Baseline visit Day 1) at T3 of each post-baseline visit, including Day 1.
| scores on a scale | CD07805/47 Gel 0.5% QD |
|---|---|
| Day 1 / Hour 3 | -1.5 ± .88 |
| Week 1/ Hour 3 | -1.4 ± .85 |
| Month 1/ Hour 3 | -1.5 ± .83 |
| Month 3 / Hour 3 | -1.7 ± .84 |
| Month 6 / Hour 3 | -1.8 ± .88 |
| Month 9 / Hour 3 | -1.7 ± .9 |
| Month 12 / Hour 3 | -1.8 ± .83 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CD07805/47 Gel 0.5% | — | 12/449 (2.7%) | 101/449 (22.5%) |
| Event | CD07805/47 Gel 0.5% |
|---|---|
| Abscess tooth w/ secondary submandibular infectionInfections and infestations | 1/449 |
| Osteoarthritis of left hipMusculoskeletal and connective tissue disorders | 1/449 |
| Advanced squamous cell carcinoma of the lungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/449 |
| COPDRespiratory, thoracic and mediastinal disorders | 1/449 |
| EncephalopathyNervous system disorders | 1/449 |
| Invasive ductal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/449 |
| Distal Esophageal Schatzki's RingGastrointestinal disorders | 1/449 |
| Unstable AnginaCardiac disorders | 1/449 |
| Right Ovarian CystReproductive system and breast disorders | 1/449 |
| Sustained Ventricular TachycardiaCardiac disorders | 1/449 |
| Event | CD07805/47 Gel 0.5% |
|---|---|
| FlushingVascular disorders | 46/449 |
| ErythemaSkin and subcutaneous tissue disorders | 35/449 |
| RosaceaSkin and subcutaneous tissue disorders | 24/449 |
| Age, Categorical(Participants) | CD07805/47 Gel 0.5% |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 395 |
| >=65 years | 54 |
| Age, Continuous(years) | CD07805/47 Gel 0.5% |
|---|---|
| Mean | 50.9 ± 12.08 |
| Sex: Female, Male(Participants) | CD07805/47 Gel 0.5% |
|---|---|
| Female | 336 |
| Male | 113 |
| Region of Enrollment(participants) | CD07805/47 Gel 0.5% |
|---|---|
| United States | 449 |
The record gives a start of Mar 2011, a primary completion of Jun 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 1 year 7 months after primary completion. A results delay was requested in Jul 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine